Warning Letter Roundup & Recap – May 12, 2015
This article was originally published in The Gray Sheet
Anybattery Inc. sold replacement batteries without premarket approval or clearance from FDA; EMcision used electronic signatures to approve numerous procedures despite not having electronic signature systems; and more. Three warning letters were listed by FDA this week.
You may also be interested in...
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.
CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.